InfuSystem adapts to ‘rapidly changing conditions’ 

ROCHESTER HILLS, Mich. – InfuSystem reported net revenues of $26.5 million for the fourth quarter ended Dec. 31, 2021, a 7.3% increase compared to the same period the prior year. Net income was $400,000. The company reported net revenues of $102.4 million for the full year, a 5.1% increase compared to the prior year. Net income was $1.4 million. “InfuSystem delivered record revenue in 2021, with revenue surpassing the $100 million mark for the first time, coming in at $102.4 million,” said CEO Richard Dilorio. “We achieved this important milestone while operating through another challenging period as the Omicron variant broadly impacted the American healthcare sector during the 2021 fourth quarter. The entire InfuSystem team did a great job of not only adapting to rapidly changing conditions, but once again maintaining industry-leading service levels for patients and providers during this difficult period.” InfuSystem reported gross margin for its DME segment was $4.3 million for the fourth quarter, representing a decrease of $400,000, or 9%, compared to the same prior year period. This decrease was due to a lower gross margin offset partially by an increase in net revenues. InfuSystem said it cannot properly forecast new revenue for fiscal year 2022 because of business start deferrals related to both Omicron and extended contracting processes. However, based on current expectations, it currently estimates approximately 20% overall revenue growth with equal top-line contributions coming from the ITS and DME segments. It expects a large new biomedical contract* to contribute much of the growth in DME, which may vary depending on the timing of when the parties finalize the contract.